Skip Navigation



Annals of Oncology Advance Access published online on June 24, 2005
Annals of Oncology, doi:10.1093/annonc/mdi355
This Article
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 3 iss...
Right arrow All Versions of this Article:
16/11/1740    most recent
mdi355v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tabernero, J.
Right arrow Articles by Baselga, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabernero, J.
Right arrow Articles by Baselga, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received April 24, 2005
Accepted April 27, 2005

Review

Novel targeted therapies in the treatment of gastric and esophageal cancer

J. Tabernero 1*, T. Macarulla 1, F. J. Ramos 1, and J. Baselga 1

1 Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain

* To whom correspondence should be addressed.
J. Tabernero, E-mail: jtabernero{at}vhebron.net


  Abstract

Esophageal cancer (EC) and gastric cancer (GC) constitute a major cause of cancer deaths worldwide. Recent improvements in both surgical techniques and adjuvant/neoadjuvant radiotherapy and chemotherapy approaches have increased the survival of patients with loco-regional disease. However, most of the patients with GC or EC have advanced disease either at diagnosis or at follow-up. Despite recent advances in the treatment of advanced disease, these patients still do poorly. An emerging understanding of the molecular pathways that characterize cell growth, cell cycle, apoptosis, angiogenesis and invasion has provided novel targets in cancer therapy. In this review we describe the current status of targeted therapies in the treatment of EC and GC. These therapeutic strategies include EGFR inhibitors, antiangiogenic agents, cell cycle inhibitors, apoptosis promoters and matrix metalloproteinases inhibitors. The emerging data from the clinical development of these compounds has provided novel opportunities in the treatment of EC and GC that will probably translate into efficacy advantage in the treatment of these common malignancies.

Keywords: targeted therapies; EGFR inhibitors; angiogenesis inhibitors; gastric cancer; esophageal cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
B. Zhu, L. Lu, W. Cai, X. Yang, C. Li, Z. Yang, W. Zhan, J.-x. Ma, and G. Gao
Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis
Mol. Cancer Ther., December 1, 2007; 6(12): 3297 - 3306.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Y. Zhao, Y. Jiang, R. Wang, X. Zheng, X. Wang, B. Jin, Y. Lu, T. Qiao, L. Hong, and D. Fan
Expression and prognostic value of MG7-Ag in patients with surgically resectable esophageal squamous cell carcinoma.
Ann. Surg. Oncol., September 1, 2007; 14(9): 2621 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Araujo, R. Ribeiro, I. Azevedo, A. Coelho, M. Soares, B. Sousa, D. Pinto, C. Lopes, R. Medeiros, and G. V. Scagliotti
Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non-Small Cell Lung Cancer--A Review of the Literature
Oncologist, February 1, 2007; 12(2): 201 - 210.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Rojo, J. Tabernero, J. Albanell, E. Van Cutsem, A. Ohtsu, T. Doi, W. Koizumi, K. Shirao, H. Takiuchi, S. R. Cajal, et al.
Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma
J. Clin. Oncol., September 10, 2006; 24(26): 4309 - 4316.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.